3,902 followers
New Research: Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers: Background: The US Food and Drug Administration (FDA)’s tumor-agnostic approval of pembrolizumab in high tumor… #celldevbio